Company Overview - The company has undergone significant changes in the last 12 to 24 months, particularly following a merger with Exscientia [1] - The current CFO and President, Ben Taylor, previously held roles as CFO and Chief Strategy Officer at Exscientia for over four years before the merger [2] Industry Insights - The transition into AI-based drug discovery was influenced by the realization that decision-making in the industry often relies on sparse data, leading to guesswork among professionals [3] - The company aims to improve data utilization in drug discovery to enhance decision-making processes [3]